Unlock Your Potential with NeuroClimax Advanced Nootropic formulation

NeuroClimax™... Read More

Unlock Your Potential with NeuroClimax Advanced Nootropic formulation

NeuroClimax™ Advanced

NeuroClimax™ Advanced is a proprietary intranasal nootropic formulation designed to support mental focus, neuronal health, mood, cognitive performance, memory, learning, coordination, mental acuity, and productivity.

The formulation is designed to support several biological processes associated with healthy brain function, including synaptic plasticity, cellular energy metabolism, neurotrophic signaling, and cognitive resilience.

How Does NeuroClimax™ Advanced Work?

NeuroClimax™ Advanced combines complementary classes of nootropic compounds that act on signaling pathways involved in neuronal communication and cognitive function.

The formulation includes:

1. Cyclic AMP-enhancing compounds, including forskolin
Forskolin is a plant-derived diterpene that activates adenylyl cyclase, leading to increased intracellular levels of cyclic AMP (cAMP). cAMP is an important second messenger involved in neuronal signaling, synaptic plasticity, memory-related pathways, and cellular metabolism.

2. Noopept
Noopept is a glutamatergic nootropic peptide derivative that has been investigated for its potential effects on learning, memory, neurotrophic signaling, and synaptic plasticity.

Together, these compounds are designed to support signaling pathways associated with increased cyclic AMP activity and neurotrophic factors such as brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF).

These signaling molecules play important roles in neuronal survival, synaptic communication, learning, memory, cellular energy metabolism, and the maintenance of neuronal networks.

Preclinical studies involving individual active compounds and related signaling pathways suggest potential effects on neuronal survival, mitochondrial function, synaptic plasticity, and oxidative-stress responses.

Scientific Rationale

NeuroClimax™ Advanced is designed around complementary mechanisms that may support:

• Neuronal signaling and synaptic plasticity

• Memory and learning

• Mental focus and cognitive performance

• Cellular energy metabolism

• Neurotrophic signaling involving BDNF and NGF

• Neuronal resilience to oxidative and metabolic stress

• Healthy motor and cognitive function

Research using cellular and animal models, including models relevant to Parkinson's disease, has shown that modulation of these signaling pathways can influence neuronal survival, neuroplasticity, mitochondrial function, and oxidative-stress responses.

Potential Benefits

NeuroClimax™ Advanced is formulated to support:

• Executive function

• Mental focus and concentration

• Memory and learning

• Mental acuity

• Productivity and cognitive performance

• Healthy mood

• Normal sleep-related brain function

• Coordination and movement

• Performance of everyday cognitive activities

• Overall cognitive resilience

Why NeuroClimax™ Advanced?

• Proprietary formulation developed in Nevada

• High-purity active ingredients

• Sterile intranasal formulation

• Designed for direct and efficient intranasal administration

• Formulated to support rapid absorption

• Designed to provide sustained cognitive support

• Manufactured in controlled sterile cleanroom environments

Active Ingredients

Cyclic AMP-enhancing compounds, including forskolin
Pharmaceutical-grade active ingredient preparation, formulated at concentrations of up to approximately 0.5%, depending on product batch and formulation specifications.

Noopept
High-purity glutamatergic nootropic compound formulated at concentrations of up to approximately 0.05%.

Enhanced formulations may also contain:

Centrophenoxine
High-purity cholinergic-support compound formulated at concentrations of up to approximately 0.3%.

The active ingredients are formulated in sterile phosphate-buffered saline at approximately physiologic pH together with selected excipients.

Excipients

The proprietary excipient system is designed to support formulation stability, solubility, sterility, and intranasal administration.

Non-active ingredients may include, at low concentrations:

• Propylene glycol

• Potassium or sodium sorbate

• EDTA

• Gamma-cyclodextrins

• Sterile phosphate-buffered saline

Cyclodextrins and other excipients are incorporated to support solubilization and formulation performance.

Safety and Manufacturing Quality

NeuroClimax™ products are manufactured and distributed by CNS Curative Technologies LLC under controlled sterile manufacturing conditions.

Manufacturing is performed in facilities designed to meet appropriate cleanroom standards, including environments classified according to ISO 14644-1:2015 cleanroom specifications.

Product batches undergo quality-control testing intended to evaluate relevant parameters such as purity, formulation integrity, microbial contamination, and selected contaminants.

Intellectual Property

NeuroClimax™ brand products are manufactured and distributed by:

CNS Curative Technologies LLC

Relevant trademark application/registration numbers include:

USPTO Nos. 98309088, 98309099, and 98309108

U.S. Patent Option Agreement:
NVRIC-OPTN-25-CNSCurative

More Information

https://www.cnscurative.com

https://www.cnscurative.store

Manufacturer

CNS Curative Technologies LLC
300 East 2nd Street
15th Floor, Suite 1512
Reno, Nevada 89501
USA

The information provided regarding NeuroClimax™ Advanced and its ingredients is based primarily on published scientific literature, mechanistic studies, and preclinical research. Findings involving individual ingredients or experimental models do not necessarily demonstrate clinical efficacy of the finished NeuroClimax™ Advanced formulation. NeuroClimax™ Advanced is intended to support cognitive and neuronal function and is not intended to diagnose, treat, cure, or prevent disease.

 

The Science and Technology

The development of NeuroClimax™ is supported by published preclinical research, patented pharmaceutical technology, and customer-discovery work funded through the National Science Foundation.

1. Published Preclinical Research

Dagda and colleagues evaluated the intranasal administration of forskolin and Noopept in a PINK1 knockout rat model of Parkinsonian pathology.

Reference:
Dagda, R., Dagda, R.Y., Mayorga, E., Martinez, B., & Gallahue, A. (2022). Intranasal Administration of Forskolin and Noopept Reverses Parkinsonian Pathology in PINK1 Knockout Rats. International Journal of Molecular Sciences, 24, 690. https://doi.org/10.3390/ijms24010690

This preclinical study provides experimental support for the use of intranasally administered nootropic compounds targeting neuronal signaling, mitochondrial function, and neurodegenerative mechanisms.

2. Patented Pharmaceutical Technology

The underlying technology is supported by U.S. intellectual property covering the use of nootropic agents for neurodegenerative disorders, including disorders associated with Parkinson's disease and Lewy body pathology.

U.S. Patent No. US11612583B2
Title: Disease-Modifying Methods for Treating Neurodegenerative Diseases Using Nootropic Agents
Inventors: Raul Y. Dagda and Ruben K. Dagda

The patent describes pharmaceutical approaches involving nootropic compounds and related therapeutic strategies for neurological and neurodegenerative conditions.

3. National Science Foundation I-Corps Support

CNS Curative Technologies LLC received support through the National Science Foundation I-Corps program to conduct customer discovery and evaluate unmet medical needs relevant to the development and commercialization of NeuroClimax™.

The I-Corps process included interviews with prospective users, patients, caregivers, healthcare stakeholders, and other relevant groups to better understand:

• Unmet needs related to cognitive and neurological health

• Patient and caregiver priorities

• Barriers associated with existing treatment approaches

• Preferences regarding delivery methods and product usability

• Potential clinical and commercial applications of NeuroClimax™ technology

Together, the published preclinical research, patented technology, and NSF-supported customer-discovery activities provide the scientific and translational foundation for the continued development of the NeuroClimax™ platform.

Disclaimers:

Not approved by FDA to label, indicate, or treat diseases.